Forge Genetics, a biotechnology company at the forefront of genetic-editing technology, has announced that Patrick Ginty, PhD, RAC (US) has been appointed to the Forge Genetics Advisory Board.
Patrick has served in multiple senior roles within the cell and gene industry and has led or supported over 50 clinical trials and contributed to the approval of 7 cell and gene therapy products globally. Patrick also previously served as co-chair of the European Regulatory Committee for the Alliance of Regenerative Medicine (ARM) and was a member of the Regulatory Advisory Committee at the Bioindustry Association (BIA) in the UK.
Forge Genetics is currently developing its proprietary technology, Forge Editing, for cell and gene therapy applications and demonstrating the technology's exceptional safety case. This includes generating platform safety and quality data using appropriate experiments and analytical techniques. Patrick’s role on the Forge Genetics Advisory board includes guiding this process and assisting Forge Genetics in navigating the regulatory landscape.
“Patrick has been instrumental in analysing and developing our road map for safety experiments that will ensure our clients' confidence in Forge Editing” - Dr Craig Woods, CEO
Patrick Ginty holds both a master’s degree and a PhD from the University of Nottingham